Loading company…
Zymeworks develops multifunctional antibody therapies for cancer, inflammation and autoimmune diseases.
Founded in 2003 and based in Vancouver, Canada, Zymeworks develops antibody therapies, including zanidatamab for HER2-positive biliary tract cancer. It works with biopharmaceutical partners through licensing agreements. In March 2026, Royalty Pharma agreed to provide USD 250 million in non-recourse royalty-backed notes, repayable from 30% of worldwide tiered royalties on Ziihera.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in